New Draft Guidance From US FDA Discusses Trials For Novel Diabetes Treatments
Executive Summary
The document discusses feasibility studies on devices that use therapies like neurostimulation or changes to the small intestine to better control blood glucose levels in people with type 2 diabetes.
You may also be interested in...
Fractyl Adds $100M Investment To Address Root Causes Of Type 2 Diabetes
The series F financing will allow the company to expand clinical research supporting its unique duodenal mucosal resurfacing approach to treating metabolic disease at its source.
AdvaMed’s MedTech ’21: Focus On MCIT, MDUFA At Hybrid Meeting
Virtual and in-person events are planned for Washington, DC, and Minneapolis, MN, during the trade group gathering.
Medtronic Beats Back Axonics’ Challenge To InterStim Patents
The US patent office has upheld all seven patents at issue, with the verdict on the final three having come on 22 September.